Abstract:
Metastatic castration-resistant prostate cancer (mCRPC) is an important problem faced by mankind and is an incurable disease that threatens the survival of men with this disease. Circulating tumor DNA (ctDNA) can be used as a noninvasive and repeatable tool for evaluating tumor genomes. It has the potential to fully improve our understanding of malignant tumors, and is increasingly being used to study mCRPC. In this paper, we reviewed the status of employment of ctDNA for detecting and monitoring mCRPC, as well as its application in investigating the mechanism of drug resistance and other relevant research. We also propose future research direction that could serve as a reference.